Aphexda (formerly motixafortide), BioLineRx’s experimental add-on therapy, greatly increased the number of blood stem cells collected for autologous stem cell transplants (ASCT), a life-extending…
News
The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by…
More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a…
ISB 1442, Ichnos Sciences’Â investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or…
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual…
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new…
Janssen and radio host and comedian D.L. Hughley are partnering to call attention to multiple myeloma in Black communities, with a goal of…
For this Myeloma Action Month (MAM), observed each March to call attention to multiple myeloma and those affected by the blood disorder, the…
The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer‘s application of its investigational under-the-skin therapy elranatamab for people with relapsed…
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy…
